Innoviva (INVA) Receivables - Net (2013 - 2026)
Innoviva's (INVA) quarterly Receivables - Net came in at $34.0 million in Q1 2026, up 103.95% YoY from $16.7 million in Q1 2025, and down 41.72% on a QoQ basis from $58.4 million in Q4 2025.
Analysis
Innoviva (INVA) Receivables - Net (2013 - 2026) Analysis & Trends
Innoviva (INVA) has 7 years of Receivables - Net data on file, last reported at $34.0 million in Q1 2026.
- Quarterly Receivables - Net rose 103.95% year-over-year to $34.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.0 million (up 103.95% YoY) and the FY2025 annual result came in at $58.4 million, down 11.55% from the prior year.
- Receivables - Net declined to $34.0 million in Q1 2026, from $58.4 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $69.6 million in Q4 2023 to a low of $6.7 million in Q3 2022.
- A 5-year average of $41.6 million and a median of $54.7 million in 2022 frame the typical range for Receivables - Net.
- Annual changes were most pronounced in 2023 — Receivables - Net surged 745.53% — and 2024, when it sank 76.56%.
- Tracing INVA's Receivables - Net over 5 years: stood at $54.7 million in 2022, then grew by 27.34% to $69.6 million in 2023, then retreated by 5.24% to $66.0 million in 2024, then decreased by 11.55% to $58.4 million in 2025, then tumbled by 41.72% to $34.0 million in 2026.
- The last three Receivables - Net figures came in at $34.0 million (Q1 2026), $58.4 million (Q4 2025), and $63.4 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Innoviva | 1.56 Bn | 984.81 Mn | 90.62 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 59.79 Mn |
| Mar 31, 2026 | 58.62 Mn |
| Dec 31, 2025 | 58.35 Mn |
| Sep 30, 2025 | 63.35 Mn |
| Jun 30, 2025 | 67.34 Mn |
| Mar 31, 2025 | 61.26 Mn |
| Dec 31, 2024 | 65.97 Mn |
| Sep 30, 2024 | 60.51 Mn |
| Jun 30, 2024 | 67.20 Mn |
| Mar 31, 2024 | 61.87 Mn |
| Dec 31, 2023 | 69.62 Mn |
| Sep 30, 2023 | 57.01 Mn |
| Jun 30, 2023 | 65.72 Mn |
| Mar 31, 2023 | 60.31 Mn |
| Dec 31, 2022 | 54.67 Mn |
| Sep 30, 2022 | 6.74 Mn |
| Dec 31, 2021 | 110.71 Mn |
| Mar 31, 2014 | 3,000.00 |
| Dec 31, 2013 | 199,000.00 |
| Sep 30, 2013 | 450,000.00 |